Impacto do uso de corticoides a nível hospitalar na sobrevida de pacientes com COVID-19
DOI:
https://doi.org/10.47224/revistamaster.v7i14.297Keywords:
SARS-COV-2, Corticosteroides, Dexametasona, Hidrocortisona, Prednisolona×Abstract
Given the current controversies regarding the treatment of hospitalized patients with COVID-19, it is necessary to
analyze articles regarding the use of corticosteroids to determine whether the risks of this therapy outweigh its
benefits. In Brazil, a higher incidence was identified in Mato Grosso and Rio de Janeiro, with a confirmed total of more
than 25 million and lethality around 2.5%. The present study was developed in order to carry out a survey of the
literature and verify the most used drug options in terms of their effectiveness. The clinical use of corticosteroids was
identified, which proved to be not so effective, but necessary and lack clinical follow-up to assess the risk and benefit.
Randomized controlled clinical trials of early administration of a low to moderate dose of methylprednisolone to
COVID-19 patients with ARDS are needed to confirm the efficacy and safety of corticosteroid therapy and to further
study long-term outcomes after discharge.
Keywords: SARS-CoV-2, Corticosteroids, Dexamethasone, Hydrocortisone, Prednisolone.
Downloads
References
ARABI, Y. M., et al., Corticosteroid therapy for critically ill patients with Middle East respiratory
syndrome. American journal of respiratory and critical care medicine, v.197, n.6, p.757-767, 2018.
BAI, C, et al. [Updated guidance on the management of COVID-19: from an American Thoracic
Society/European Respiratory Society coordinated International Task Force. European Respiratory Review
[Internet]. v.29, n.157, p.1-15, 2020.
Bhimraj, et al. Infectious Diseases Society of America Guidelines on the treatment and management of
patients with coronavirus disease 2019 (COVID-19). Clinical Infectious Diseases, ciaa478, 2020.
Braz-de-Melo HA, et al. The Use of the Anticoagulant Heparin and Corticosteroid Dexamethasone as
Prominent Treatments for COVID-19. Frontiers in Medicine. v.8, p.615333, 2021.
CALY, L, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral
Research. v.178, p.104787, 2020.
CÂMARA, FP, CARDOSO, D, CÂMARA, P, MORENO, M. Contágio e virulência: covid-19 e a próxima pandemia.
Brazilian Journal of Health Review. v.3, n5, p.3353-7, 2020.
CAVALCANTI, AB, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. New
England Journal of Medicine, v.383, n.21, p.2041-52, 2020.
BRASIL. Coronavírus Brasil. Painel Coronavírus. 2022. [Internet]. Disponível em: https://covid.saude.gov.br/
DEQUIN, P. F., et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill
patients with COVID-19: a randomized clinical trial. Jama, v.324, n.13, 1298-1306, 2020.
Edalatifard, M., Akhtari, M. et al. Intravenous methylprednisolone pulse as a treatment for hospitalised
severe COVID-19 patients: results from a randomised controlled clinical trial. European Respiratory
Journal, v.56, n.6, 2020.
Fadel, et al. Early short-course corticosteroids in hospitalized patients with COVID-19. Clinical Infectious
Diseases, v.71, n.16, p.2114-2120, 2020.
FAQ COVID-19 DA SBI – Sociedade Brasileira de Imunologia. 2022 [Internet]. Disponível em:
https://sbi.org.br/2021/03/16/faq-covid-19-da-sbi-2/
Gautret, P., et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label
non-randomized clinical trial. International journal of antimicrobial agents, v.56, n.1, p.105949, 2020.
GROUP RC, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. The New
England Journal of Medicine. v.384, n.8, p.693–704, 2020.
GUAN, Wei-jie et al. Clinical characteristics of coronavirus disease 2019 in China. New England journal of
medicine, v. 382, n. 18, p. 1708-1720, 2020.
HUANG, Chaolin et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The
lancet, v. 395, n. 10223, p. 497-506, 2020.
Jeronimo, C. M. P., et al. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus
disease 2019 (COVID-19; Metcovid): a randomized, double-blind, phase IIb, placebo-controlled trial. Clinical
Infectious Diseases, v.72, n.9, p.e373-e381, 2021.
KO, JJ, et al. A Comparison of Methylprednisolone and Dexamethasone in Intensive Care Patients With COVID.
Journal of Intensive Care Medicine, v.36, n.6, p.673-80, 2021.
LI, Huan et al. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERSCoV infection: a systematic review and meta-analysis. Leukemia, v. 34, n. 6, p. 1503-1511, 2020.
MASKIN, L. P., et al. High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary
to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials, v.21, n.1,
p.1-3, 2020.
MINA, M. J., PARKER, R., LARREMORE, D. B. Rethinking Covid-19 test sensitivity—a strategy for
containment. New England Journal of Medicine, v.22, n.383, e120, 2020.
Moreno, G., et al. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a
propensity score matching study. Intensive care medicine, v.44, n.9, p.1470-1482, 2018.
PEERI, N. C, et al.. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest
global health threats: what lessons have we learned? International journal of epidemiology, v.3, n.49,p.
-726, 2020.
Petersen, M. W., et al., Low‐dose hydrocortisone in patients with COVID‐19 and severe hypoxia (COVID
STEROID) trial-protocol and statistical analysis plan. Acta Anaesthesiologica Scandinavica, v.64, n.9, p.1365-
, 2020.
Pinzón MA, et al. Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia. PLOS ONE, v.16,
n.5, p.e0252057, 2021.
Ranjbar K., et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment
of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infectious Diseases,
v.21, n.1, p.1–8, 2021.
Rosas, I. O., et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal
of Medicine, v.384, n.16, 1503-1516, 2021.
SIDDELL, S. G. et al. Coronaviridae. Intervirology, v. 20, n. 4, p. 181-189, 1983.
SILVA, Daylane Fernandes; DE OLIVEIRA, Maria Liz Cunha. Epidemiologia da COVID-19: comparação entre
boletins epidemiológicos. Comunicação Em Ciências Da Saúde, v. 31, p. 61-74, 2020.
Sterne, J. A. et al. Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a
study protocol for a prospective meta-analysis of randomized trials. Trials, v.21, n.1, p.1-3, 2020
Tomazini BM, et al. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and
rationale for a randomized trial. Revista Brasileira de Terapia Intensiva, v.32, n.3, p.354–62, 2020.
VILLAR, J., et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre,
randomised controlled trial. The Lancet Respiratory Medicine, v.8, n.3, p.267–76, 2020.
WILLIAMS, D. M. Clinical pharmacology of corticosteroids. Respiratory care, v.63, n.6, p.655-670, 2018
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Revista Master - Ensino, Pesquisa e Extensão
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Política para Periódicos de Acesso Livre
Autores que publicam nesta revista concordam com os seguintes termos:
a) A licença desses direitos autorais abrange o direito exclusivo da Revista Master - Ensino, Pesquisa e Extensão para reproduzir, publicar e distribuir o artigo,
nacional e internacionalmente, incluindo reimpressões, traduções, reproduções fotográficas, microformas, formulários eletrônicos (offline, on-line) ou qualquer outra reprodução de natureza similar.
b) O (s) autor (es) aprovam que o manuscrito não pode ser retirado ou reenviado para qualquer outro Jornal/Revista enquanto a avaliação pelos pares estiver em andamento. Após aprovado o manuscrito, um autor pode auto-arquivar uma versão de seu artigo em seu próprio site e/ou em seu repositório institucional.
c) O (s) autor (es) declaram que são integralmente responsáveis pela totalidade do conteúdo da contribuição e que a Revista Master - Ensino, Pesquisa e Extensão e o corpo editorial da Revista Científica do estão expressamente isentos de qualquer responsabilidade sobre o conteúdo do artigo, métodos, técnicas e resultados de sua pesquisa, tendo, assim, finalidade meramente informativa e educativa.
d) Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
